1. Home
  2. EQH vs CYTK Comparison

EQH vs CYTK Comparison

Compare EQH & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Equitable Holdings Inc.

EQH

Equitable Holdings Inc.

N/A

Current Price

$49.36

Market Cap

13.3B

Sector

Finance

ML Signal

N/A

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

N/A

Current Price

$71.40

Market Cap

10.7B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
EQH
CYTK
Founded
1859
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Insurers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.3B
10.7B
IPO Year
2017
2004

Fundamental Metrics

Financial Performance
Metric
EQH
CYTK
Price
$49.36
$71.40
Analyst Decision
Buy
Strong Buy
Analyst Count
11
19
Target Price
$56.82
$89.26
AVG Volume (30 Days)
2.6M
1.9M
Earning Date
05-04-2026
05-05-2026
Dividend Yield
2.60%
N/A
EPS Growth
N/A
N/A
EPS
0.50
N/A
Revenue
$11,665,000,000.00
$13,368,000.00
Revenue This Year
$43.13
$7.37
Revenue Next Year
$7.45
$310.19
P/E Ratio
$100.26
N/A
Revenue Growth
N/A
N/A
52 Week Low
$35.20
$47.22
52 Week High
$55.15
$88.31

Technical Indicators

Market Signals
Indicator
EQH
CYTK
Relative Strength Index (RSI) 48.28 38.45
Support Level $47.10 $59.19
Resistance Level $49.39 $79.66
Average True Range (ATR) 1.10 2.17
MACD -0.26 -0.45
Stochastic Oscillator 16.81 26.41

Price Performance

Historical Comparison
EQH
CYTK

About EQH Equitable Holdings Inc.

Equitable Holdings Inc is a financial services company providing retirement, asset management, and wealth management solutions for individual and institutional clients, operating through three segments. The Retirement segment generates the majority of revenue and offers annuities, retirement savings plans, institutional savings products, and includes the spread lending business. The Asset Management segment provides diversified investment management and related services globally through Institutional, Retail, and Private Wealth channels and reflects the business of AB. The Wealth Management segment offers advisory accounts, financial planning and advice, life insurance, and annuity products. Revenues are earned predominantly from fee income, income from investments, and insurance premiums.

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. The company's product, named as MYQORZO, is an allosteric and reversible inhibitor of cardiac myosin motor activity. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

Share on Social Networks: